Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt

- Jiang, Chen Chen, Yang, Fan, Thorne, Rick F., Zhu, Bi Ke, Hersey, Peter, Zhang, Xu Dong

Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor–related apoptosis-inducing ligand

- Zhuang, Liqing, Lee, C. Soon, Scolyer, Richard A., McCarthy, Stanley W., Zhang, Xu Dong, Thompson, John F., Screaton, Gavin, Hersey, Peter

Inhibition of apoptosis facilitates necrosis induced by cisplatin in gastric cancer cells

- Zhang, Lin Jie, Hao, Yuan Zhang, Hu, Chun Song, Ye, Yan, Xie, Qi Peng, Thorne, Rick F., Hersey, Peter, Zhang, Xu Dong

Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma

- Hersey, Peter, Nguyen, T., Farrelly, M., Menzies, S.W., Hirst, D., Johnson, H., Coventry, B., Collins, S.

Melanoma cell sensitivity to docetaxal-induced apoptosis is determined by class III β-tubulin levels

- Mhaidat, Nizar M., Thorne, Rick F., De Bock, Charles Edo, Zhang, Xu Dong, Hersey, Peter

Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells

- Jiang, Chen Chen, Mao, Zhi Gang, Avery-Kiejda, Kelly A., Hersey, Peter, Zhang, Xu Dong

Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737

- Lucas, Keryn M., Mohana-Kumaran, Nethia, Lau, Diana, Zhang, Xu Dong, Hersey, Peter, Huang, David C., Weninger, Wolfgang, Haass, Nikolas K., Allen, John D.

MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma

- Jin, Lei, Hu, Wang Lai, Hersey, Peter, Zhang, Xu Dong, Wu, Mian, Jiang, Chen Chen, Wang, Jia Xu, Han, Chuan Chun, Chu, Ping, Zhang, Lin Jie, Thorne, Rick F., Wilmott, James, Scolyer, Richard A.

Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma

- Zhuang, Liquing, Scolyer, Richard A., Lee, C. Soon, McCarthy, Stanley W., Cooper, Wendy A., Zhang, Xu Dong, Thompson, John F., Hersey, Peter

Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma

- Bowden, Nikola A., Ashton, Katie A., Scott, Rodney J., Vilain, Ricardo E., Avery-Kiejda, Kelly A., Davey, Ryan J., Murray, Heather C., Budden, Timothy, Braye, Stephen G., Zhang, Xu Dong, Hersey, Peter

Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab

- Hodi, F. Stephen, Hwu, Wen-Jen, Joshua, Anthony M., Hersey, Peter, Dronca, Roxana, Joseph, Richard, Hille, Darcy, Xue, Dahai, Li, Xiaoyun Nicole, Kang, S. Peter, Ebbinghaus, Scot, Perrone, Andrea, Kefford, Richard, Wolchok, Jedd D., Weber, Jeffrey S., Daud, Adil, Hamid, Omid, Patnaik, Amita, Ribas, Antoni, Robert, Caroline, Gangadhar, Tara C.

Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries

- Wainstein, Alberto, Algarra, Salvador Martin, Whitaker, Dagmar, Quirt, Ian, Hauschild, Axel, Rutkowski, Piotr, Bastholt, Lars, Cinat, Gabriela, Demidov, Lev, Grob, Jean Jacques, Guo, Jun, Hersey, Peter, Espinosa, Enrique, Schachter, Jacob

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720

- Jiang, Chen Chen, Lai, Fritz, Thorne, Rick F., Yang, Fan, Liu, Hao, Hersey, Peter, Zhang, Xu Dong

Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma

- Hersey, Peter, Zhang, Xu Dong

Somatic copy number amplification and hyperactivating somatic mutations of EZH2 correlate with DNA methylation and drive epigenetic silencing of genes involved in tumor suppression and immune responses in melanoma

- Tiffen, Jessamy, Wilson, Stephen, Gallagher, Stuart J., Hersey, Peter, Filipp, Fabian V.

The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance

- Wroblewski, David, Mijatov, Branka, Mohana-Kumaran, Nethia, Lai, Fritz, Gallagher, Stuart J., Haass, Nikolas K., Zhang, Xu Dong, Hersey, Peter

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

- Kirkwood, John M., Lorigan, Paul, Hersey, Peter, Hauschild, Axel, Robert, Caroline, McDermott, David, Marshall, Margaret A., Gomez-Navarro, Jesus, Liang, Jane Q., Bulanhagui, Cecile A.

The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells

- Tseng, Hsin-Yi, Chen, Li Hua, Ye, Yan, Tay, Kwang Hong, Jiang, Chen Chen, Guo, Su Tang, Jin, Lei, Hersey, Peter, Zhang, Xu Dong

Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein

- Chen, Li Hua, Jiang, Chen Chen, Watts, Ralph, Thorne, Rick F., Kiejda, Kelly A., Zhang, Xu Dong, Hersey, Peter

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with Carboplatin and Paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

- Hauschild, Axel, Agarwala, Sanjiv S, Peschel, Christian, Schadendorf, Dirk, Garbe, Claus, O'Day, Steven, Daud, Adil, White, J. Michael, Xia, Chenghua, Patel, Kiran, Kirkwood, John M., Keilholz, Ulrich, Trefzer, Uwe, Hogg, David, Robert, Caroline, Hersey, Peter, Eggermont, Alexander, Grabbe, Stephan, Gonzalez, Rene, Gille, Jens